Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agios Pharmaceuticals, a company engaged in discovering and developing novel drugs in the field of cancer metabolism, has named Scott Biller as the new chief scientific officer of the company.
Subscribe to our email newsletter
Most recently, Biller has worked for Novartis as the vice president and head of global discovery chemistry at the Novartis Institutes for BioMedical Research (NIBR).
Befor joining Novartis, Biller was the vice president of Pharmaceutical Candidate Optimisation at the Bristol Myers Squibb (BMS) Pharmaceutical Research Institute, and executive director of Drug Discovery Chemistry for the BMS research site in Lawrenceville, NJ.
Agios Pharma, CEO David Schenkein said that Scott’s breadth of experience and record of leadership in the industry makes him the ideal candidate to shape and lead our research initiatives.